Conventional Magnetic Resonance Imaging

PROCEDURE3 trials

Sponsors

National Cancer Institute (NCI), M.D. Anderson Cancer Center

Conditions

Combined Hepatocellular Carcinoma and CholangiocarcinomaConstitutional Mismatch Repair Deficiency SyndromeLynch SyndromeMalignant GliomaMalignant Solid NeoplasmRecurrent Brain NeoplasmRecurrent Childhood EpendymomaRecurrent Diffuse Intrinsic Pontine Glioma

Phase 1

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Active, not recruitingNCT02359565

National Cancer Institute (NCI)Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma +8

Start: 2015-06-03End: 2027-01-16Updated: 2026-04-03

Phase 2

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Active, not recruitingNCT05211323

National Cancer Institute (NCI)Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer

Start: 2022-12-07End: 2026-06-30Target: 88Updated: 2026-04-03

Unknown Phase

Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis

CompletedNCT04870645

M.D. Anderson Cancer CenterMalignant Solid Neoplasm

Start: 2021-03-30End: 2023-08-29Updated: 2024-11-06

Related Papers

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas

Neurological Research and Practice2023-10-198 citations